Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Altimmune Stock Is Surging Today

By Cory Renauer – Jun 16, 2021 at 1:06PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

An experimental new weight loss drug produced compelling data in an early stage clinical trial.

What happened

Shares of Altimmune (ALT -5.17%), a clinical-stage biopharmaceutical company, are on the move following a positive clinical readout. Investors excited about the company's potential new weight loss drug drove the stock 23% higher as of 12:34 p.m. on Wednesday. 

So what 

Altimmune's weight loss drug candidate, ALT-801, is a GLP-1 receptor agonist that also activates glucagon receptors. There are other GLP-1 drugs out there that promote weight loss by regulating appetites. Boosting energy expenditure by acting on glucagon receptors, though, could give ALT-801 a unique advantage over Saxenda and Wegovy from Novo Nordisk (NVO -2.71%).

Investor checking on their stocks at a desk.

Image source: Getty Images.

Selling anti-obesity drugs has been a lucrative business for Novo Nordisk. Saxenda's a daily injection that produces around $1.0 billion in sales and is categorized as a weight loss drug even though its main ingredient is the same as that of the company's popular diabetes drug, Victoza. It's still early, but it looks as if Altimmune's candidate could challenge Novo Nordisk's dominance in this space.

During the first part of a two-part phase 1 study that should enroll more than 80 volunteers, a 1.8 mg weekly injection of ALT-801 each week lowered volunteers' body weight by 5.4% after six weeks. Body weights among patients randomized to receive placebos increased by 0.9% on average.

Now what

Before getting too excited about Altimmune's results, you should know that weekly injections with Wegovy led to long-term weight reductions that were more dramatic than the six-week interim results Altimmune shared today. In other words, investors should probably wait and see if the weight reductions measured after six weeks are still happening when the company reports 12-week data in the third quarter.

Altimmune finished March with $226.5 million in cash after burning through $14.9 million in the first quarter. The company's cash burn rate will probably rise a great deal in 2021 as more clinical trials with ALT-801 as a treatment for different patient groups begin.

Altimmune is also running phase 2 clinical trials with AdCOVID, a potential COVID-19 vaccine booster. If ALT-801 doesn't keep delivering impressive results in larger trials, raising enough capital to fund all this activity could get extremely difficult. 

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Altimmune, Inc. Stock Quote
Altimmune, Inc.
ALT
$11.73 (-5.17%) $0.64
Novo Nordisk A/S Stock Quote
Novo Nordisk A/S
NVO
$95.28 (-2.71%) $-2.65

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.